Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study

Overview of attention for article published in Breast Cancer Research and Treatment, June 2016

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 33 Dimensions

Readers on

mendeley: 84 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 1 X users, with an upper bound of 1,051 followers.

Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic… https://t.co/jVqGYXKAFq #breastcancer

Reply Repost Favourite

Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic… https://t.co/SFA6lbTIhT #breastcancer

Reply Repost Favourite

Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic… https://t.co/cEuuCenOFb #breastcancer

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.